KMT5A and ovarian cancer: Previous studies suggest a polymorphism rs16917496 T>C, which is located within the miR-502 binding site in SET8 3′UTR (Figure 1A), modulates SET8 protein expression, and thus contributes to breast cancer and ovarian cancer susceptibility, and clinical outcome of hepatocellular carcinoma [35], [36], [37].